NEUROLOGY 2004;63:214-219
© 2004 American Academy of Neurology
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
C. Holmes, MBChB MRCPsych, PhD,
D. Wilkinson, MBChB FRCPsych,
C. Dean, RMN,
S. Vethanayagam, MBBS,
S. Olivieri, MD FRCPsych,
A. Langley, MBChB,
N. D. Pandita-Gunawardena, MBBS FRCP,
F. Hogg, BM MRCPsych,
C. Clare, MBBS MRCPsych and
J. Damms, MBChB MRCPsych
From the Memory Assessment and Research Centre (Dr. Holmes, D. Wilkinson, C. Dean, and C. Clare), University of Southampton; Department of Mental Health for the Elderly (S. Vethanayagam), St Leonards on Sea; Melbury Lodge (Dr. Olivieri), Winchester; Pepperville House (A. Langley), Littlehampton; University Hospital Lewisham (N.D. Pandita-Gunawardena), Lewisham, London; and St James Hospital (F. Hogg and J. Damms), Portsmouth, UK.
Address correspondence and reprint requests to Dr. Clive Holmes, University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Rd., Southampton, UK; e-mail: c.holmes{at}soton.ac.uk
Objective: To determine the efficacy of donepezil in the treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a randomized withdrawal study.
Method: Patients with mild to moderate AD with marked neuropsychiatric symptoms at baseline (Neuropsychiatric Inventory [NPI] > 11 points) were treated openly with donepezil 5 mg daily for 6 weeks followed by 10 mg daily for a further 6 weeks. Patients were then randomized (60:40) to either placebo or 10 mg donepezil daily. All patients were assessed at 6 weeks and provided there was no marked cognitive deterioration their blinded treatment was continued for a further 6 weeks. NPI and carer distress were assessed at 6 weekly intervals throughout the study.
Results: A total of 134 patients participated. Following randomization patients who continued on donepezil 10 mg for 12 weeks had improvements in NPI compared with the placebo group (mean change –2.9 vs 3.3 points; ITT-LOCF p = 0.02) and in NPI-Distress scores (median change –2.0 vs 1.0 points; ITT-LOCF p = 0.01). During the open-label phase the total NPI and NPI-Distress scores were lower after 12 weeks treatment with open label donepezil compared with baseline (total NPI 22 points vs13 points; ITT-LOCF p < 0.0001; NPI-Distress 13.5 vs 7.9 points; ITT-LOCF p < 0.0001). In the open-label phase all domains of the NPI (with the exception of elation) were improved (all p < 0.05 after Bonferroni correction).
Conclusions: Donepezil has significant efficacy in the treatment of neuropsychiatric symptoms in patients with mild to moderate AD.
Received January 5, 2004.
Accepted in final form March 23, 2004.
See also page 200
This article has been cited by other articles:
|
|
|
|
 
P. H. Lu, S. D. Edland, E. Teng, K. Tingus, R. C. Petersen, J. L. Cummings, and On behalf of The Alzheimer's Disease Cooperative S
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Neurology,
June 16, 2009;
72(24):
2115 - 2121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Winblad
Review: Donepezil in Severe Alzheimer's Disease
American Journal of Alzheimer's Disease and Other Dementias,
June 1, 2009;
24(3):
185 - 192.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. A. Smith
Treatment of Alzheimer's disease in the long-term-care setting
Am. J. Health Syst. Pharm.,
May 15, 2009;
66(10):
899 - 907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Burns and S. Iliffe
Alzheimer's disease
BMJ,
February 5, 2009;
338(feb05_1):
b158 - b158.
[Full Text]
|
|
|
|
|
|
|
A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al.
Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians
Ann Intern Med,
March 4, 2008;
148(5):
370 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Ann Intern Med,
March 4, 2008;
148(5):
379 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Howard, E. Juszczak, C. G. Ballard, P. Bentham, R. G. Brown, R. Bullock, A. S. Burns, C. Holmes, R. Jacoby, T. Johnson, et al.
Donepezil for the Treatment of Agitation in Alzheimer's Disease
N. Engl. J. Med.,
October 4, 2007;
357(14):
1382 - 1392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Farlow
Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease
Mayo Clin. Proc.,
October 1, 2006;
81(10):
1350 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ratain, T. Eisen, W. M. Stadler, K. T. Flaherty, S. B. Kaye, G. L. Rosner, M. Gore, A. A. Desai, A. Patnaik, H. Q. Xiong, et al.
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol.,
June 1, 2006;
24(16):
2505 - 2512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Holloway Jr. and R. F. Jozefowicz
Update in neurology.
Ann Intern Med,
March 21, 2006;
144(6):
421 - 426.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Rosenberg
Translational Research on the Way to Effective Therapy for Alzheimer Disease
Arch Gen Psychiatry,
November 1, 2005;
62(11):
1186 - 1192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kaduszkiewicz, T. Zimmermann, H.-P. Beck-Bornholdt, and H. van den Bussche
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
BMJ,
August 6, 2005;
331(7512):
321 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Sink, K. F. Holden, and K. Yaffe
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
JAMA,
February 2, 2005;
293(5):
596 - 608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B Standridge
Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease
Evid. Based Ment. Health,
November 1, 2004;
7(4):
112 - 112.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Herrmann and D. Knopman
Donepezil therapy for neuropsychiatric symptoms in AD: Methods make the message
Neurology,
July 27, 2004;
63(2):
200 - 201.
[Full Text]
[PDF]
|
|
|
|
